key: cord-0897672-r618oc5u
authors: Cheng, A.; Riedel, S.; Arnaout, R.; Kirby, J. E.
title: Verification of the Abbott Alinity m Resp-4-Plex Assay for detection of SARS-CoV-2, influenza A/B, and respiratory syncytial virus
date: 2021-04-22
journal: nan
DOI: 10.1101/2021.04.22.21255133
sha: da04855f81aab6f6b35910a2c490086598791f9f
doc_id: 897672
cord_uid: r618oc5u

COVID-19 symptomology may overlap with those of other circulating respiratory virus. In the future, hospital epidemiology will be focused on viruses with the potential for causation of severe disease, and there will be additional need for detection of respiratory viruses with potential sequelae for which there are specific and potential life-saving treatments. Therefore, there will be increasing need for multiplex respiratory assays to detection such virus. The Abbott Alinity m Resp-4-Plex assay is a multiplex PCR assay that simultaneously detects and differentiates infection with SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV). Based on perceived assay utility, we characterized the new assay in a series of validation studies to characterize its accuracy, precision, and analytical sensitivity. All were found to be robust within the measures examined. In the context of sample-to-answer, near random access automation on the Alinity m platform, we believe that the Resp-4-Plex assay offers significant utility in addressing the needs of the current SARS-CoV-2 pandemic and especially in the future with anticipated endemic circulation of SARS-CoV-2 with other respiratory viruses.

SARS-CoV-2, influenza A/B, and RSV may cause respiratory infection with significant 16 morbidity and mortality. Respiratory disease signs and symptoms for these viruses overlap, and, 17 therefore, it is not possible to reliably differentiate between them on clinical grounds alone, 18 especially early during the course of disease. SARS-CoV-2 and influenza, especially, have 19 significant implications in terms of transmission inside and outside of hospital settings and 20 therefore require reliable methods for diagnosis. RSV, although primarily thought of as a serious 21 pathogen in young children, can also cause bronchiolitis and pneumonia in adults. Depending on 22 the stage of illness, there are therapeutics with varying efficacy for SARS-CoV-2, influenza, and 23 RSV. Therefore, sensitive detection and differentiation of these viruses are valuable clinical 24 determinations. 25

With social distancing and masking during the COVID pandemic, the circulation of 26 influenza and other respiratory viruses almost ceased in many locations (1). Presumably, 27 however, with less than 100% vaccine efficacy for influenza, waning immunity to circulating 28 respiratory viruses over a large population cohort, and reopening of our societies, circulation of 29 influenza and RSV will rebound and likely exceed normal levels for some time (2). At the same 30 time, SARS-CoV-2 will likely become endemic, potentially adopting a seasonal cycle with 31 enhanced transmission during the winter as observed in the United States during the winters of 32 2020 and 2021 (3). It will therefore be critical to be able to test both patients and staff for high 33 consequence respiratory pathogens to avert potential nosocomial transmission and to identify the 34 most advantageous therapeutic options for patients with serious illness. 35

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 4 A multiplex testing option for high consequence testing options would address these 36 specific diagnostic needs. The Abbott Alinity m Resp-4-Plex assay in March 2021 received 37 emergency use authorization designation for detection of SARS-CoV-2, influenza A, influenza B 38 and RSV. Approved sample types are either a nasopharyngeal swab collected by a health care 39 provider or a nasal swab specimen self-collected in a healthcare setting. The multiplex, reverse-40 transcription real-time PCR assay targets the RdRp and N genes of SARS-CoV2: the matrix gene 41 of influenza A; the nonstructural 1 gene of influenza B, and the matrix gene of RSV. An internal 42 control is spiked into each sample in the form of armored RNA encoding a segment of the 43 hydroxypyruvate reductase gene from the pumpkin plant, Cucurbita pepo. It controls for 44 appropriate extraction and amplification in each reaction. Each amplicon is detected by a real-45 time probe with a distinct fluorophore with the exception that both probes for the SARS-CoV-2 46 targets are detected with the same fluorophore. The primers and probes for the SARS-CoV-2 47 target are the same as those used in the singleplex Abbott RealTime SARS-CoV-2 and Alinity m 48 SARS-CoV-2 assays, whose performance characteristics have been examined in prior literature 49 (4-6). Cycle threshold numbers (Ct) determined on the Alinity m instrument in the Resp-4-Plex 50 assay are determined based on a fluorescence cutoff. They are used along with the inflection 51 point of the amplification curve at the maximum amplification efficiency (the max ratio) (7) for 52 qualitative assessment of target positivity and negativity (personal communication, Joshua 53 Kostera, Abbott Molecular). 54

Here we describe characterization of accuracy, precision, and limit of detection of the 55

Alinity m Resp-4-Plex assay determined as part of normal quality assurance activities prior to 56 adoption for clinical use in our clinical laboratory. 57 58 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Accuracy. Results from prior determinations either by Cepheid Xpert® Xpress Flu; direct 60 fluorescent antigen testing for influenza A/B, RSV, adenovirus, and parainfluenza 1, 2 and 3 61 and/or shell vial culture on R-Mix-Too monolayers (Quidel Corporation, San Diego, CA); 62 and/or reference laboratory testing at Eurofin ViraCor using the TEM-PCR assay (8) were 63 considered predicate comparator assays as enumerated. Samples were divided for Resp-4-Plex 64 testing on the two Alinity m instruments at our institution. As there was no difference in 65 performance on these identical systems results are presented in aggregate. Discrepant resolution 66 included repeat testing of samples as available using Resp-4-Plex on the second Alinity m 67 platform and/or using the Cepheid Xpert® Xpress SARS-CoV-2/Flu/RSV assay. Data for 68 individual sample is listed in Table S1 . values obtained from each screening concentration, and PCR efficiency was determined using 80 slope of the regression line using the ThermoFisher calculator: 81 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.22.21255133 doi: medRxiv preprint 6 https://www.thermofisher.com/us/en/home/brands/thermo-scientific/molecular-82 biology/molecular-biology-learning-center/molecular-biology-resource-library/thermo-83 scientific-web-tools/qpcr-efficiency-calculator.html. Three dilutions bracketing the potential 84

limit of detection cutoff were tested again with twenty replicates each to establish the LoD for 85 each analyte. The 95% detection threshold and confidence intervals were extrapolated by 86

Logistic regression in Prism 9 for MacOS (GraphPad, San Diego, CA). LoD analysis was only 87 performed on a single Alinity m instrument. 88 89

Accuracy 91

To determine accuracy, the Resp-4-Plex assay was run using clinical samples that were 92 previously determined to be positive for the constituent viruses. Ten samples previously 93 determined to be SARS-CoV-2 positive using the Alinity m SARS-CoV-2 singleplex assay 94 were tested using Resp-4-Plex. All were positive for SARS-CoV-2. Although the Ct values for 95 SARS-CoV-2 on Resp-4-Plex were a mean -1.81 +/-0.58 lower than fractional cycle numbers 96 on the singleplex assay, the assays were highly correlated with one another (R 2 = 0.99) (Fig  97   1A) . 98

Twelve samples previously determined to be influenza A positive by Cepheid Xpress 99

Flu were tested using Resp-4-Plex. All tested positive influenza A. A single sample tested with 100

Resp-4-Plex also yielded a positive RSV result with a high Ct value of 32.46 (see limit of 101 detection analysis below). The test was repeated using Resp-4-Plex on the second Alinity m 102 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.22.21255133 doi: medRxiv preprint 7 instrument and gave qualitatively and quantitatively almost identical results. The sample was 103 then tested using the Cepheid Xpress SARS-CoV-2/Flu/RSV assay and was influenza A 104 positive, RSV negative. This sample was interpreted as a potential Xpress RSV false negative 105 based on low viral load. 106

Ten samples previously determined to be influenza B positive using the Cepheid Xpress 107

Flu assay were tested using Resp-4-Plex. All tested positive for influenza B. A single sample 108 tested with Resp-4-Plex also yield a positive RSV result. The test was repeated using Resp-4-109

Plex on the second Alinity m instrument and gave similar results. The sample was then tested 110 using the Cepheid Xpress SARS-CoV-2/Flu/RSV assay and was influenza B positive, RSV 111 positive. This sample was resolved as an influenza B/RSV true positive. 112

Ten samples previously determined to be RSV positive using a combination of direct 113 fluorescence antigen testing and/or shell vial culture and a single sample determined to be RSV 114 positive by TEM-PCR were tested using Resp-4-Plex. All were positive for RSV. 115

Eighteen samples previously determined to be negative for viruses by direct fluorescent 116 antigen testing and/or shell vial culture, five of which were also negative by TEM-PCR, were 117 tested using Resp-4-Plex. Sixteen samples were negative for the viruses detected by Plex For SARS-CoV-2, the LoD screen demonstrated excellent linearity with R 2 = 0.98 and a 136 97% PCR efficiency (Fig. 1B) . The manufacturer's claimed LoD was confirmed through twenty 137 replicates at 50, 25 and 10 copies/mL using the SeraCare reference material, yielding 100%, 138 100% and 80% detection, respectively. The LoD was therefore <= 25 copies per mL with an Ct 139 value of 35.72 +/-0.54 at 25 copies/mL. The logistic regression was non-convergent and 140 therefore an extrapolated LoD could not be established. 141

For influenza A, the LoD screen demonstrated excellent linearity with R 2 = 0.97 and 142 93% PCR efficiency. The manufacturer's claimed LoD was confirmed through twenty 143 replicates at 50, 25 and 10 copies/mL using the SeraCare reference material,yielding 100%, 144 80% and 30% detection, respectively. The LoD was therefore <= to 50 copies per mL with an 145

Ct value of 37.18+/-0.67 at 50 copies/mL. By logistic regression, the LoD was 47 copies/mL 146 (95% confidence interval ~25-125 copies/mL). 147

For influenza B, the LoD screen demonstrated excellent linearity with an R 2 = 0.97 and a 148 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101/2021.04.22.21255133 doi: medRxiv preprint 9 101% PCR efficiency. The manufacturer's claimed LoD was confirmed through twenty 149 replicates at 50, 25 and 10 copies/mL using the SeraCare reference material, yielding 100%, 150 90% and 70% detection, respectively. The LoD was therefore <= to 50 copies per mL with an 151 Ct value of 35.94+/-0.73 at 50 copies/mL. By logistic regression, the LoD was 36 copies/mL 152 (95% confidence interval ~18-178 copies/mL). 153

For RSV, the LoD screen demonstrated excellent linearity with an R 2 = 0.97 and 97% 154 PCR efficiency. The manufacturer's claimed LoD was confirmed through twenty replicates at 155 50, 25 and 10 copies/mL using the SeraCare reference material, yielding 100%, 90% and 75% 156 detection, respectively. The LoD was <= to 50 copies per mL with an Ct value of 35.75 +/-0.70 157 at 50 copies/mL. By logistic regression the LoD was 39.8 copies/mL (95% confidence interval 158 ~18-1000 copies/mL). 159 160 Precision 161 Intra-run precision was determined by using pooled samples, positive for each of the 162 four viruses, and a negative pool. Each pool was tested in quadruplicate on each of the two 163 Alinity m instruments with each individual test for each specific virus performed on each of the 164 Assay Processing Units (APU) #1 through #4 on each instrument, so that every APU was tested 165 during the precision testing. Inter-run precision was verified by testing the pools for each virus 166 on each alinity m instrument again on additional two separate days. Qualitative intra-run and 167 inter-run precision results were 100% correlated as expected. 168

Although Resp-4-Plex is a qualitative assay, we also assessed quantitative precision by 169 comparison of Ct values in replicates. Coefficients of variation (CV) varied from 0.6 to 2.5% 170 across all viruses tested on both instruments in intra-run precision comparisons and from 0.4% 171 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 to 2.9% in inter-run precision comparisons. The precision of the Ct values for positive controls 172 run during the validation on Alinity m #1 (n=4) and Alinity m #2 (n=5) instruments, run once 173 per day of testing, was also examined. C.V.'s on individual instruments for each assay were all 174 less than 1%. There was no statistical difference between the positive control Ct values run on 175 Alinity #1 and Alinity #2 for the four viruses (Fig. 1C) , with significance considered P <= 0.05, 176 with comparisons performed using the Kruskall-Wallis test. Therefore, reproducibility of both 177 instruments appeared essentially identical for the Resp-4-Plex assay. 178 179

The Resp-4-Plex assay is welcome addition to targeted respiratory panel options that 181 will be necessary in a post-COVID world. It appeared highly accurate, sensitive, and precise. 182

The three descrepancies with comparator methods, specifically detection of co-infections, could 183 be attributed to enhanced detection by Resp-4-Plex. This was because: (1) the second virus was 184 detected on repeat testing by Resp-4-Plex on a second Alinity m platform, (2) the second virus 185 was detected by the alternative Cepheid respiratory panel, and/or (3) the second virus had a 186 very high Ct value, near its limit of detection, and therefore plausibly may have been below the 187 limit of detection of the comparator assays. Overall, our experience was consistent with 188 qualitative detection data described in the EUA product insert, although our data set was 189 significantly smaller in size. 190

Notably, the LoD for each individual virus was robust with high amplification 191 efficiencies even in the context of a multiplex assay and testing of quality control material in 192 which all four targets were present in equivalent amounts. In fact, the limit of detection for 193 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 SARS-CoV-2 in Resp-4-Plex (~25 copies/mL) was below that determined in our analysis of the 194 SARS-CoV-2 SinglePlex assay (~50 copies/mL, data not shown). The multiplex and singleplex 195 SARS-CoV-2 assays were also extremely well correlated (R 2 = 0.99). 196 Furthermore, the Ct values were also log-linearly correlated with the quantitative 197 standard at and above the limit of detection of the assays with excellent PCR efficiencies. 198

Notably, Ct values or their equivalent (e.g. fractional cycle number (7)) may vary significantly 199 between platforms at the same viral load level and for difference viruses (9). Furthermore, they 200 vary inversely with viral load which is intuitively confusing to end users. We ultimately believe 201 that SARS-CoV-2 results should be reported selectively as a viral load, as most intuitively 202 understood by clinicians, benchmarked against a universal standard (6). In particular, there are 203 several situations where viral load values are helpful, for example, to distinguish between 204 reinfection versus persistent low levels of mRNA that may last months after a prior infection, 205

and to evalute likely infectivity in the appropriate contexts. The log-linear performance of the 206

Resp-4-Plex assays suggest that future conversion to a quantitative readout, i.e., a viral load, 207 should easily be supported and we believe will provide additional utility for patient 208 management. Furthermore, our previous study with the Abbott RealTime SARS-CoV-2 assay 209 (6) and the singleplex Alinity m SARS-CoV-2 assay (data not shown) supports a method for 210 accurately calculating the viral load from Ct measurements without the absolute need for a 211 standard curve, and/or extending viral load determinations beyond limits of available calibrator 212 material. 213

Taken together, we verified the performance characteristis of a new molecular multiplex 214 respiratory panel assay on the Alinity m molecular system.. This platform notably provides high 215 throughput; sample-to-answer, random access and semi-batch functionality with a 115 minute 216 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 sample to answer turn around time for prioritized specimens; and an ability to load and perform 217 multiple different tests at one time. We believe this assay and platform will be especially useful 218 in fulfilling future needs, in situations where SARS-CoV-2, influenza A, influenza B and RSV 219 circulate at significant levels, and where these viruses need to be detected and differentiated for 220 optimal patient management. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Decreased Influenza Activity During the COVID-19 Pandemic -United 230

The impact 233 of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic 234 infections

Is 236 coronavirus disease (COVID-19) seasonal? A critical analysis of empirical and

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021